Duchenne Muscular Dystrophy Gene Therapy Resumes Shipments After FDA Reversal: A Closer Look

In a surprising turn of events, the U.S. Food and Drug Administration has given the green light for Sarepta Therapeutics to resume shipments of its Elevidys gene therapy for Duchenne muscular dystrophy to younger patients who are able to walk. This decision comes on the heels of a temporary halt in shipments after the unfortunate deaths of two older boys.

Initially reluctant to comply with the FDA’s request to suspend shipments, Sarepta now faces a challenging path to reintroducing the product to the market. The FDA’s reversal was influenced, in part, by the backlash from the Duchenne patient community, highlighting the importance of patient voices in regulatory decisions. Moving forward, the FDA remains committed to engaging with and addressing concerns from those impacted by Duchenne muscular dystrophy.